MRNA Stock Summary and Trading Ideas (Moderna | NASDAQ:MRNA)

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna trades on the NASDAQ stock market under the symbol MRNA.

As of September 18, 2026, MRNA stock price declined to $154.04 with 16,793,261 million shares trading.

MRNA has a beta of 0.48, meaning it tends to be less sensitive to market movements. MRNA has a correlation of 0.00 to the broad based SPY ETF.

MRNA has a market cap of $61.09 billion. This is considered a Large Cap stock.

Last quarter Moderna reported $145 million in Revenue and -$1.97 earnings per share. This beat revenue expectation by $41 million and exceeded earnings estimates by $.10.

In the last 3 years, MRNA traded as high as $176.66 and as low as $22.28.

The top ETF exchange traded funds that MRNA belongs to (by Net Assets): VTI, VOO, VB, VBR, IVV.

MRNA has outperformed the market in the last year with a price return of +505.3% while the SPY ETF gained +16.8%. MRNA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +140.8% and +5.8%, respectively, while the SPY returned +2.3% and -0.9%, respectively.

MRNA support price is $148.96 and resistance is $167.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNA shares will trade within this expected range on the day.